- Home
- GOOD vs RIGL Comparison
GOOD vs RIGL Comparison
Compare GOOD & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOOD | RIGL |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | United States | United States |
| Employees | 72 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.9M | 628.4M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | GOOD | RIGL |
|---|---|---|
| Price | $11.62 | $26.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $12.50 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 400.6K | 369.9K |
| Earning Date | 05-06-2026 | 03-03-2026 |
| Dividend Yield | ★ 10.26% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 19.48 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $10.37 | N/A |
| Revenue Next Year | $2.56 | $12.23 |
| P/E Ratio | $62.41 | ★ $1.34 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $10.33 | $15.50 |
| 52 Week High | $15.12 | $52.24 |
Technical Indicators
Market Signals| Indicator | GOOD | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 38.35 | 31.37 |
| Support Level | $11.25 | $26.38 |
| Resistance Level | $11.80 | $31.26 |
| Average True Range (ATR) | 0.25 | 1.29 |
| MACD | -0.11 | -0.05 |
| Stochastic Oscillator | 20.88 | 26.28 |
Price Performance
Historical ComparisonAbout GOOD Gladstone Commercial Corporation Real Estate Investment Trust
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.